Your browser doesn't support javascript.
Industry 4.0 Technologies for the Manufacturing and Distribution of COVID-19 Vaccines.
Sarfraz, Azza; Sarfraz, Zouina; Sarfraz, Muzna; Abdul Razzack, Aminah; Bano, Shehar; Singh Makkar, Sarabjot; Thevuthasan, Sindhu; Paul, Trissa; Khawar Sana, Muhammad; Azeem, Nishwa; Felix, Miguel; Cherrez-Ojeda, Ivan.
  • Sarfraz A; Larkin Community Hospital, South Miami, FL, USA.
  • Sarfraz Z; The Aga Khan University, Karachi, Pakistan.
  • Sarfraz M; Larkin Community Hospital, South Miami, FL, USA.
  • Abdul Razzack A; Fatima Jinnah Medical University, Lahore, Pakistan.
  • Bano S; Larkin Community Hospital, South Miami, FL, USA.
  • Singh Makkar S; King Edward Medical University, Lahore, Pakistan.
  • Thevuthasan S; Larkin Community Hospital, South Miami, FL, USA.
  • Paul T; Fatima Jinnah Medical University, Lahore, Pakistan.
  • Khawar Sana M; Larkin Community Hospital, South Miami, FL, USA.
  • Azeem N; Larkin Community Hospital, South Miami, FL, USA.
  • Felix M; Larkin Community Hospital, South Miami, FL, USA.
  • Cherrez-Ojeda I; Larkin Community Hospital, South Miami, FL, USA.
J Prim Care Community Health ; 13: 21501319211068638, 2022.
Article in English | MEDLINE | ID: covidwho-1607687
ABSTRACT

BACKGROUND:

The evolutionary stages of manufacturing have led us to conceptualize the use of Industry 4.0 for COVID-19 (coronavirus disease 2019), powered by Industry 4.0 technologies. Using applications of integrated process optimizations reliant on digitized data, we propose novel intelligent networks along the vaccine value chain. Vaccine 4.0 may enable maintenance processes, streamline logistics, and enable optimal production of COVID-19 vaccines. VACCINE 4.0 FRAMEWORK The challenge in applying Vaccine 4.0 includes the requirement of large-scale technologies for digitally transforming manufacturing, producing, rolling-out, and distributing vaccines. With our framework, Vaccine 4.0 analytics will target process performance, process development, process stability, compliance, quality assessment, and optimized maintenance. The benefits of digitization during and post the COVID-19 pandemic include first, the continual assurance of process control, and second, the efficacy of big-data analytics in streamlining set parameter limits. Digitization including big data-analytics may potentially improve the quality of large-scale vaccine production, profitability, and manufacturing processes. The path to Vaccine 4.0 will enhance vaccine quality, improve efficacy, and compliance with data-regulated requirements.

DISCUSSION:

Fiscal and logistical barriers are prevalent across resource-limited countries worldwide. The Vaccine 4.0 framework accounts for expected barriers of manufacturing and equitably distributing COVID-19 vaccines. With amalgamating big data analytics and biometrics, we enable the identification of vulnerable populations who are at higher risk of disease transmission. Artificial intelligence powered sensors and robotics support thermostable vaccine distribution in limited capacity regions, globally. Biosensors isolate COVID-19 vaccinations with low or limited efficacy. Finally, Vaccine 4.0 blockchain systems address low- and middle-income countries with limited distribution capacities.

CONCLUSION:

Vaccine 4.0 is a viable framework to optimize manufacturing of vaccines during and post the COVID-19 pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Prim Care Community Health Year: 2022 Document Type: Article Affiliation country: 21501319211068638

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Prim Care Community Health Year: 2022 Document Type: Article Affiliation country: 21501319211068638